On March 4, 2026 Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, reported that new data evaluating DecisionDx-Melanoma’s i31-SLNB test result for prediction of sentinel lymph node (SLN) positivity will be presented at the Society of Surgical Oncology (SSO) 2026 Annual Meeting, being held March 5-7 in Phoenix.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"The initial reports from the same prospective, multicenter study confirmed the performance of DecisionDx-Melanoma to both (i) impact sentinel lymph node biopsy (SLNB) decision-making and (ii) identify patients at low risk of nodal metastasis," said Rebecca Critchley-Thorne, Ph.D., vice president, research and development, at Castle Biosciences. "The data being presented at SSO 2026 further extend this growing body of evidence supporting the use of DecisionDx-Melanoma to guide risk-aligned management decisions consistent with National Comprehensive Cancer Network guideline risk thresholds, including whether to forgo, consider or pursue SLNB."
Castle will share the following ePoster at SSO: EP49: The integrated 31-gene expression profile test identifies patients with T1b–T2a cutaneous melanoma who can safely avoid sentinel lymph node biopsy.
DecisionDx-Melanoma’s i31-SLNB algorithm integrates the independent 31-GEP score with key clinicopathologic factors, including Breslow thickness, ulceration, mitotic rate and age. This integrated approach was developed and independently validated to provide more precise risk estimation than staging criteria alone. By combining tumor biology with traditional clinical features, the algorithm generates a personalized likelihood of SLN positivity, supporting risk-aligned shared decision-making for SLNB, a surgical staging procedure commonly used to assess nodal metastasis risk.
ePosters will be available for viewing in the SSO 2026 Exhibit Hall, on the SSO Annual Meeting website and within the SSO Mobile App. The ePoster gallery will be accessible to registered attendees.
For more information on DecisionDx-Melanoma and the poster above, please visit Castle at booth #321.
About DecisionDx-Melanoma
DecisionDx-Melanoma is a gene expression profile (GEP) test designed to analyze tumor biology to deliver a personalized risk assessment for patients with stage I–III cutaneous melanoma, enhancing risk stratification beyond American Joint Committee on Cancer (AJCC) staging alone. By combining molecular insights with select clinicopathologic features, the test provides two distinct outputs: a personalized risk of sentinel lymph node (SLN) positivity and a personalized risk of recurrence and/or metastasis. This clinically actionable information is designed to help guide risk-aligned patient management decisions, including SLN biopsy consideration, follow-up intensity, imaging and referrals.
DecisionDx-Melanoma is supported by more than 50 peer-reviewed publications, including prospective studies and meta-analyses, and was developed in collaboration with more than 100 leading U.S. institutions. The test has been clinically validated in more than 10,000 patient samples, ordered more than 220,000 times since launch, and has been shown to be associated with improved patient survival. Learn more at www.CastleBiosciences.com.
(Press release, Castle Biosciences, MAR 4, 2026, View Source [SID1234663270])